# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2020 Earnings Results

**Report date:** 2021-02-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2020

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.03%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.53 | N/A | +34.04% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's performance, highlighting the strong EPS results. They emphasized their commitment to innovation and growth.

**Key quotes:**

> We are pleased with our strong EPS performance this quarter.

> Our focus remains on delivering innovative therapies.

### Guidance Changes

No guidance data was provided for future quarters.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and potential for future profitability. The stock's slight increase reflects investor approval of the earnings results, despite the lack of revenue data or guidance. Overall, the company appears to be on a solid path, but investors will be looking for more comprehensive financial details in future reports.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2020_